Oncothyreon Inc (USA)  

(Public, NASDAQ:ONTY)   Watch this stock  
Find more results for Nasdaq:ONTY
1.63
+0.01 (0.62%)
Mar 3 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.59 - 1.65
52 week 1.48 - 4.08
Open 1.61
Vol / Avg. 428,934.00/757,095.00
Mkt cap 170.19M
P/E     -
Div/yield     -
EPS -0.40
Shares 105.06M
Beta 0.88
Inst. own 52%
Mar 4, 2015
Oncothyreon Inc at Cowen Health Care Conference - 8:40AM EST - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -27.78% -46.37%
Return on average equity -30.76% -50.38%
Employees 43 -
CDP Score - -

Address

Suite 500, 2601 Fourth Avenue
SEATTLE, WA 98121
United States - Map
+1-206-8012100 (Phone)
+1-206-8012101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company�s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Its lead product candidate, tecemotide (formerly known as L-BLP25 or Stimuvax), is being evaluated for the treatment of non-small cell lung cancer (NSCLC). It has granted worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of tecemotide. It is conducting a Phase I trial for ONT-10, a cancer vaccine directed against the same target as tecemotide. It is also collaborating with Array BioPharma Inc. (Array) to develop and commercialize ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor.

Officers and directors

Robert L. Kirkman M.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Julia Marie Eastland Chief Financial Officer, Vice President - Corporate Development, Secretary
Age: 49
Bio & Compensation  - Reuters
Gary Christianson Chief Operating Officer
Age: 59
Bio & Compensation  - Reuters
Scott Peterson Ph.D. Chief Scientific Officer, Vice President - Research & Development
Age: 52
Bio & Compensation  - Reuters
Diana Hausman M.D. Chief Medical Officer, Vice President - Clinical Development
Age: 50
Bio & Compensation  - Reuters
Christopher S. Henney Ph.D. Non-Executive Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Ted W. Love M.D. Director
Age: 55
Bio & Compensation  - Reuters
Richard L. Jackson Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Daniel K. Spiegelman Independent Director
Age: 55
Bio & Compensation  - Reuters
W Vickery Stoughton Independent Director
Age: 68
Bio & Compensation  - Reuters